SNPMiner Trials (Home Page)
Report for Mutation I1171N
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.
NCT02419287 Anaplastic Large Cell Lymphoma, ALK-Positive Drug: crizotinib MeSH:Lymphoma Lymphoma, Large-Cell, Anaplastic
HPO:Anaplastic large-cell lymphoma Lymphoma
Although crizotinib shows activity, relapses occur typically within 5 months after starting treatment and were supported by mutations like I1171N. --- I1171N ---
Primary Outcomes
Measure: objective response rates (ORR) in subjects with ALK+ lymphomas resistant or refractory to standard cytotoxic treatment, according to RECIST 1.1 criteria. Time: the entire duration of the study (5 years)Measure: Duration ORR Time: the entire duration of the study (5 years)
Secondary Outcomes
Measure: Progression free survival (PFS) in ALK+ lymphoma patients treated with crizotinib, that are resistant or refractory to standard cytotoxic treatment. Time: the entire duration of the study (5 years)Measure: Number of patients with adverse events after crizotinib treatment Time: the entire duration of the study (5 years)
Measure: Quality of Life (QoL) in this population of patients using the the EORTC - C30 Quality of Life questionnaire Time: the entire duration of the study (5 years)
Measure: Overall survival (OS) in ALK+ lymphoma patients treated with crizotinib Time: the entire duration of the study (5 years)